Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1,5-dicyclooctyl thiocarbohydrazone is a synthetic thiocarbohydrazone derivative investigated for its potential anti-cancer properties, particularly against cervical cancer. Synthesized via the reaction of cyclooctanone and thiocarbohydrazide, the compound has demonstrated antiproliferative activity against the human cervical cancer cell line SiHa. Molecular docking studies indicate that its mechanism of action likely involves the inhibition of the viral oncoprotein E6, a critical factor in the progression of HPV-related malignancies. Beyond its biological activity, the compound also exhibits notable non-linear optical properties, suggesting potential utility as a pharmaceutical intermediate or a precursor for new heterocyclic medicinal derivatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1,5-dicyclooctyl thiocarbohydrazone.